Millennium Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-500,000
| Closed | -$925K | – | 7089 |
|
|
2023
Q1 | $925K | Sell |
500,000
-1,328,681
| -73% | -$1.65M | ﹤0.01% | 4164 |
|
|
2022
Q4 | $2.03M | Buy |
+1,828,681
| New | +$2.6M | ﹤0.01% | 3551 |
|
|
2022
Q3 | – | Sell |
-82,739
| Closed | -$251K | – | 7698 |
|
|
2022
Q2 | $251K | Buy |
+82,739
| New | +$402K | ﹤0.01% | 5507 |
|
|
2022
Q1 | – | Sell |
-69,540
| Closed | -$581K | – | 7832 |
|
|
2021
Q4 | $581K | Sell |
69,540
-171,685
| -71% | -$1.41M | ﹤0.01% | 4923 |
|
|
2021
Q3 | $1.79M | Sell |
241,225
-217,091
| -47% | -$1.34M | ﹤0.01% | 4052 |
|
|
2021
Q2 | $3.12M | Buy |
458,316
+280,088
| +157% | +$2.33M | ﹤0.01% | 3383 |
|
|
2021
Q1 | $1.83M | Buy |
178,228
+130,333
| +272% | +$1.43M | ﹤0.01% | 3619 |
|
|
2020
Q4 | $335K | Buy |
47,895
+24,966
| +109% | +$194K | ﹤0.01% | 4489 |
|
|
2020
Q3 | $187 | Buy |
22,929
+7,184
| +46% | +$44.5K | ﹤0.01% | 4087 |
|
|
2020
Q2 | $109K | Sell |
15,745
-50,381
| -76% | -$272K | ﹤0.01% | 3970 |
|
|
2020
Q1 | $314K | Buy |
66,126
+1,837
| +3% | +$10.6K | ﹤0.01% | 3153 |
|
|
2019
Q4 | $561K | Sell |
64,289
-94,294
| -59% | -$510K | ﹤0.01% | 3315 |
|
|
2019
Q3 | $528K | Buy |
+158,583
| New | +$635K | ﹤0.01% | 3224 |
|
|
2019
Q1 | – | Sell |
-218,024
| Closed | -$735K | – | 4431 |
|
|
2018
Q4 | $735K | Sell |
218,024
-422,237
| -66% | -$1.97M | ﹤0.01% | 2743 |
|
|
2018
Q3 | $4.16M | Sell |
640,261
-38,916
| -6% | -$289K | 0.01% | 1942 |
|
|
2018
Q2 | $5.2M | Buy |
679,177
+433,281
| +176% | +$6.25M | 0.01% | 1789 |
|
|
2018
Q1 | $5.5M | Sell |
245,896
-125
| -0.1% | -$2.77K | 0.01% | 1741 |
|
|
2017
Q4 | $3.14M | Buy |
246,021
+186,068
| +310% | +$2.74M | ﹤0.01% | 2001 |
|
|
2017
Q3 | $934K | Sell |
59,953
-144,793
| -71% | -$2.05M | ﹤0.01% | 2558 |
|
|
2017
Q2 | $2.87M | Sell |
204,746
-89,116
| -30% | -$1.91M | 0.01% | 1856 |
|
|
2017
Q1 | $6.46M | Buy |
+293,862
| New | +$6.23M | 0.01% | 1298 |
|
Other funds holding JNCE
Millennium Management's JNCE Position: Q2 2023 in Review
Millennium Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 500,000 shares — an estimated $925K sold.
Millennium Management first reported a position in JNCE in Q1 2017 and held it in 21 quarters. The position peaked at $6.46M in Q1 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Millennium Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Millennium Management sold 500,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $925K.
- Millennium Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 21 quarters.
- Millennium Management's Jounce Therapeutics, Inc. Common Stock position peaked at $6.46M in Q1 2017.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.